Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
- Resource Type
- Article
- Authors
- Zabalza, Ana; Arrambide, Georgina; Otero-Romero, Susana; Pappolla, Agustín; Tagliani, Paula; López-Maza, Samuel; Cárdenas-Robledo, Simón; Esperalba, Juliana; Fernández-Naval, Candela; Martínez-Gallo, Monica; Castillo, Mireia; Bonastre, Mercè; Resina-Salles, Mireia; Bertran, Jordina; Rodriguez-Barranco, Marta; Carbonell-Mirabent, Pere; Gonzalez, Marina; Merchan, Miguel; Quiroga-Varela, Ana; Miguela, Albert
- Source
- Multiple Sclerosis Journal. Jun2022, Vol. 28 Issue 7, p1138-1145. 8p.
- Subject
- *HUMORAL immunity
*SARS-CoV-2
*COVID-19 vaccines
*VACCINE effectiveness
*AUTOIMMUNE diseases
*MULTIPLE sclerosis
- Language
- ISSN
- 1352-4585
Background: The effect of disease-modifying therapies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is unclear. Objectives: We aim to determine the immunological responses to SARS-CoV-2 in multiple sclerosis (MS) and anti-CD20-treated patients with other autoimmune diseases (AID). Methods: Humoral and cellular responses we determined before and 30-90 days after vaccination in patients with MS and anti-CD20-treated patients with other AID in two Catalan centers. Results: 457 patients were enrolled. Findings showed that humoral response decreased under anti-CD20s or sphingosine 1-phosphate receptor modulators (S1PRM) and with longer treatment duration and increased after 4.5 months from the last anti-CD20 infusion. Cellular response decreased in S1PRM-treated. Patients on anti-CD20 can present cellular responses even in the absence of antibodies. Conclusion: Anti-CD20s and S1PRM modify the immunological responses to SARS-CoV-2 vaccines. [ABSTRACT FROM AUTHOR]